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Isolation and characterization of a scFv antibody specific for
tumor endothelial marker 1 (TEM1), a new reagent for targeted
tumor therapy
Abstract
Tumor endothelial marker 1 (TEM1) is a protein predominantly expressed on the cell surface of
endothelial cells in newly developing blood vessels and on tumor cells. It is therefore ideally suited as a
target for anti-angiogenic tumor therapy. Using phage display technology a single chain antibody
fragment (scFv-CM6) was isolated that specifically binds to the extracellular part of TEM1. Antibody
specificity was determined in ELISA, by Western analysis, fluorescence microscopy and flow cytometry
performed with TEM1-expressing cells. ScFv-CM6 was further functionalized and coupled to
liposomes. Such immunoliposomes loaded with the cytotoxic drug
N4-octadecyl-1-beta-D-arabinofuranosylcytosine-(5'-5')-3'-C-ethinylcytidine showed increased binding
affinity and up to 80% higher cytotoxic activity towards TEM1-expressing IMR-32 tumor cells
compared with control liposomes.
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Abstract
Tumor endothelial marker 1 (TEM1) is a protein predominantly expressed on the cell surface of endothelial cells in newly
developing blood vessels and on tumor cells. It is therefore ideally suited as a target for anti-angiogenic tumor therapy. Using
phage display technology a single chain antibody fragment (scFv-CM6) was isolated that specifically binds to the extracellular
part of TEM1. Antibody specificity was determined in ELISA, by Western analysis, fluorescence microscopy and flow
cytometry performed with TEM1-expressing cells. ScFv-CM6 was further functionalized and coupled to liposomes. Such
immunoliposomes loaded with the cytotoxic drug N4-octadecyl-1-b-D-arabinofuranosylcytosine-(5 0-5 0)-3 0-C-ethinylcytidine
showed increased binding affinity and up to 80% higher cytotoxic activity towards TEM1-expressing IMR-32 tumor cells
compared with control liposomes.
q 2005 Elsevier Ireland Ltd. All rights reserved.
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The formation of new blood vessels from pre-
existing vasculature, a process called angiogenesis, is
essential for tumor growth [1]. Tumor endothelial
marker 1 (TEM1) was first identified with0304-3835/$ - see front matter q 2005 Elsevier Ireland Ltd. All rights re
doi:10.1016/j.canlet.2005.04.029
* Corresponding author. Tel.:C41 56 310 4165; fax:C41 56 310
5288.
E-mail address: kurt.ballmer@psi.ch (K. Ballmer-Hofer).a monoclonal antibody as a protein specifically
expressed on tumor endothelial cells and was called
endosialin by Rettig et al. [2]. Using ‘serial analysis of
gene expression’ (SAGE) technology, TEM1 was
again identified by St. Croix et al. as a tumor
endothelial cell surface protein predominantly
expressed on newly forming blood vessels [3,4].
However, Opavsky et al. showed that the expression
of this protein is more widespread [5]. An association
with tumor development has been suggested again
recently by the finding that TEM1 expression isCancer Letters 235 (2006) 298–308www.elsevier.com/locate/canletserved.
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tumors [6,7]. TEM1 is a 165 kDa glycoprotein
classified as a C-type lectin-like membrane receptor
and is conserved in humans and mice. Its extracellular
part consists of five globular domains (N-terminal
C-type lectin domain, sushi-like domain, and three
epidermal growth factor (EGF)-like repeats) and a
mucin-like region. The core protein is heavily
sialylated and displays similarity to thrombomodulin
[8]. The normal function of human TEM1/endosialin
is still unknown. Due to its increased expression on
endothelial cells, its potential as a target molecule for
tumor diagnosis and therapy has been proposed. Since
TEM1 is located on the surface of tumor endothelial
cells, it represents an easily accessible target in solid
tumor tissue for antibody- or antibody conjugate-
mediated therapeutic intervention. Therapeutic
targeting of the tumor vasculature, rather than the
tumor cells themselves, has several advantages;
firstly, endothelial cells are highly accessible for
circulating drugs or drug carriers, secondly, endo-
thelial cells are genetically stable and therefore less
likely developing resistance towards cytotoxic drugs.
Phage display and recombinant techniques have
been employed to isolate single chain antibody
fragments (scFvs) specific for a broad variety of
antigens [9,10]. ScFvs have also been successfully
fused to a range of molecules in order to introduce
different functionalities and secondary activity
domains. Radioisotopes for cancer imaging, enzymes
for prodrug therapy, toxins for targeted cell killing,
viruses for gene therapy, liposomes for improved
systemic delivery and biosensors for real-time
detection of target molecules in live cells are among
the most common applications of scFvs [11–16].
Liposomes are widely used as delivery systems to
target specific tissues using a broad spectrum of
agents including chemotherapeutics, imaging agents,
antigens, lipids and DNA. Targeting of liposomes to
specific sites of drug action is achieved by attachment
of antibodies or antibody fragments to their surface.
The resulting immunoliposomes show specific bind-
ing in vitro and in vivo and increased tumor to normal
tissue distribution ratios [17,18].
We generated a scFv, scFv-CM6, with selectivity
for the extracellular domains of the TEM1 protein
using phage display technology. Its binding specificity
was tested on purified protein in ELISA and Westernblot analysis and on cells expressing TEM1 by
fluorescence microscopy and flow cytometry. Specific
binding of anti-TEM1-modified-scFv-liposomes
(scFv-CM6-C-immunoliposomes) was demonstrated
on the TEM1-expressing human neuroblastoma tumor
cell line IMR-32 [2]. Anti-tumor activity of scFv-
CM6-C-immunoliposomes was evaluated by loading
with N4-octadecyl-1-b-D-arabinofuranosylcytosine-
(5 0-5 0)-3 0-C-ethinylcytidine (NOAC-ETC), an amphi-
philic cytotoxic compound which belongs to a new
class of heterodinucleoside dimers that combine a
lipophilic ara-C derivative (NOAC) [19] cytidine
(ETC) [20], which inhibits both RNA and DNA
synthesis.2. Materials and methods
2.1. Chemicals
The pGEX-2TK/GST-TEM1 vector was a kind
gift of Dr. B. Vogelstein and Dr. K. W. Kinzler
(Johns Hopkins Oncology Center, Baltimore, Mary-
land). The ETH-2 human antibody phage library
was a generous gift of Prof. D. Neri (ETH Zu¨rich,
Switzerland). Goat anti-flag M2 antibody and goat
anti-mouse IgG conjugated with horseradish peroxi-
dase (HRP) were obtained from Sigma (Buchs,
Switzerland). Fluorescein isothiocyanate (FITC)
labeled goat anti-mouse IgG, tetramethyl-rhodamine
isothiocyanate (TRITC) labeled goat anti-mouse
IgG, alkaline phosphatase (AP) conjugated goat
anti-rabbit IgG and AP conjugated goat anti-mouse
IgG were from Southern Biotechnology Associates,
Inc. (Birmingham, USA) and rabbit anti-GST IgG
from Santa Cruz Biotechnology (Santa Cruz, USA).
BM Blue POD substrate and WST-1 reagent
were obtained from Roche Diagnostics (Rotkreuz,
Switzerland). Isopropylthiogalactoside (IPTG) was
from Bachem AG (Bubendorf, Switzerland). Dul-
becco’s modified Eagles medium (DMEM), fetal
bovine serum and all media supplements were
supplied by Invitrogen Life Technology (San
Diego, CA). Phospholipon 90G (hydrogenated soy
phosphatidyl choline (HSPC)) was from Nattermann
Phospholipid GmbH (Ko¨ln, Germany) and
1,2-Dipalmitoyl-sn-glycero-3-phoshoethanolamine
(DPPE) from Sygena Ltd. (Liestal, Switzerland).
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(Buchs, Switzerland) and 3,3 0-dioctadecyloxacarbo-
cyanine perchlorate (DiO) from Molecular Probes
(Leiden, The Netherlands). Sulfosuccinimidyl
N-(carboxycyclohexylmethyl) maleimide (sulfo-
SMCC) was from Pierce (Lausanne, Switzerland).
N4-octadecyl-1-b-D-arabinofuranosylcytosine-(5 0-5 0)-
3 0-C-ethinylcytidine (NOAC-ETC) was synthesized
as described for similar dimers [19]. All buffer salts
and other chemicals were of analytical grade and
were obtained from Fluka or Sigma (Buchs,
Switzerland).
2.2. Cell lines
Human embryonic kidney cells (HEK) 293T were
maintained in DMEM. The human neuroblastoma cell
line IMR-32 and the human colon carcinoma cell line
HT-29 were a kind gift from Dr. I. Novak (Paul
Scherrer Institut, Switzerland) and were maintained in
RPMI 1640 medium supplemented with 1.5 mM
sodium pyruvate and MEM non-essential amino
acids. Each medium was completed with 10% fetal
bovine serum (FBS), 1% L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 50 U/ml
nystatin. The cells were cultured at 37 8C in an
atmosphere of 5% CO2.
2.3. Generation of DNA constructs
The bicistronic plasmid pIRES (BD Biosciences
Clontech, Germany) was modified to encode the
signal sequence of the human vascular endothelial
growth factor receptor 2 (VEGFR-2) followed by the
extracellular TEM1 sequence and the transmembrane
domain of VEGFR-2, giving rise to the vector
pIRES/VE2-ss-TEM1-TM. The part of TEM1 was
amplified from pGEX-2TK/GST-TEM1 by PCR
using the forward 5 0-GGAGACCCGGGCC-
GACCCCTGGGCTGCTGAG-3 0 and reverse
5 0-GCCGTGCCTACTAGAATAATGATCCAGCC
A CCGTTGAAGGC-3 0 primers (Microsynth AG,
Switzerland). The insertion of the PCR fragment into
pIRES/VE2-ss-TM was accomplished using a PCR
subcloning technique [21]. The pPICZaA_scFv-
CM6-C plasmid for the expression of the functiona-
lized scFv was constructed as described by Marty
et al. [15].2.4. Production and purification of GST-TEM1
E. coli XL10 gold cells transformed with pGEX-
2TK/GST-TEM1 or pGEX-2TK (Amersham Phar-
macia Biotech, Sweden) plasmid were grown in LB
medium containing ampicillin (100 mg/ml) until they
had reached the mid-log phase where they were
induced with isopropylthiogalactoside (IPTG,
0.2 mM). Cells were harvested by centrifugation
after 4 h expression at 28 8C. Cell pellets were
resuspended in lysis buffer (50 mM Tris–HCl, 5 mM
EDTA, 10% glycerol, pH 7.4) in the presence of 1%
Triton X-100, 1 mM phenylmethylsulfonylfluoride
(PMSF), and 150 mg/ml lysozyme and the suspen-
sion was sonicated for 5 min. The soluble protein
extract was isolated by centrifugation (10 000 g,
15 min, 4 8C) and purified by Glutathione-Sepharose
column chromatography (Amersham Pharmacia
Biotech, Sweden). The pure protein was eluted
with freshly prepared 10 mM reduced glutathione
in PBS (0.137 M NaCl, 2.68 mM KCl, 8.09 mM
Na2HPO4, 1.76 mM KH2PO4). Expression
and isolation of the target protein was monitored
by SDS-PAGE and the identity was confirmed
by Western blotting using a rabbit anti-GST
antibody.
2.5. Selection of specific scFv antibodies
by biopanning
The construction of the library and the phage
preparation was performed according to the method
described by Pini et al. [9]. ScFv selection was carried
out using GST-TEM1 as template as described by
Rubio et al. [22] with the following minor change: for
a first round of negative selection, the phage library
was incubated at room temperature (RT) in GST-
coated tubes.
2.6. Expression and purification of scFvs in E. coli
and P. pastoris and purification
Production of the scFvs in E. coli HB2152 was
carried out as described by Rubio et al. [22].
Production of scFvs in P. pastoris X-33 was
carried out as described by Marty et al. [15].
ScFvs were purified on a Protein A column
(Amersham Pharmacia Biotech, Sweden) according
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100 mM glycine, pH 2.5 using an Aekta prime
instrument column (Amersham Pharmacia Biotech,
Sweden). Expression and isolation of the target
protein was monitored by SDS-PAGE and the
identity was confirmed by Western blotting using
a mouse anti-flag M2 antibody.2.7. Enzyme-linked immunosorbent assay (ELISA)
ELISA microtiter plates (Nunc GmbH, Wiesba-
den, Germany) were coated overnight at 4 8C with
10 mg/ml GST-TEM1, GST or BSA, respectively.
After coating the plates were washed five times with
PBS and blocked for 2 h at RT with 2% MPBS (2%
milk in PBS). A concentration range of 0.01–
1000 nM purified scFvs prepared in 2% MPBS were
incubated in the wells for 1 h at RT. Binding of
scFvs was detected after 1 h incubation with mouse
anti-flag M2 antibody and HRP-conjugated goat
anti-mouse IgG prepared in 2% MPBS at RT. The
color reaction was initiated by the addition of BM
Blue POD substrate as described by the manufac-
turer and stopped with 1 M H2SO4 after 15 min. The
absorbance was read at 410 nm using a Dynatech
microplate reader.2.8. Binding of scFvs to immobilized GST-TEM12.8.1. Immobilization on PVDF membrane
The GST-TEM1 protein samples were analyzed
on SDS-PAGE under reducing conditions and
transferred onto a polyvinylidene (PVDF) membrane
(Immobilon-P, Millipore, Switzerland). After block-
ing with MTBST (10 mM Tris–HCl, pH 8, 150 mM
NaCl, 0.05% Tween supplemented with 2% milk)
the membrane was incubated with scFvs (2 mg/ml)
in MTBST for 1 h at RT. The detection on
the membrane was completed by reaction with
mouse anti-flag M2 and goat AP-conjugated
anti-mouse antibodies, both in TBST, followed by
color development with 36.6 mM 5-bromo-4-chloro-
indolylphosphate and 97.6 mM nitroblue-tetrazolium
in DMF. Similarly, GST proteins were detected
using a rabbit anti-GST IgG as primary and goat
AP-conjugated anti-rabbit IgG as secondary
antibody.2.8.2. Immobilization on Glutathione beads
Glutathione-Sepharose beads were incubated with
1 mg/ml of GST or GST-TEM1, respectively, for 2 h
at 4 8C according to the manufacturer’s protocol. The
beads were washed twice with PBS and incubated
with scFv (20 mg/ml) for another 2 h at 4 8C. After
washing twice with 0.5 M LiCl and 0.1 M Tris–HCl,
pH 8, the beads were resuspended in SDS-PAGE
loading buffer and boiled for 5 min at 95 8C. SDS-
PAGE was performed and the proteins were
transferred to an Immobilon-P transfer membrane
and detected as described above.
2.9. Immunofluorescence
HEK 293T cells were transiently transfected with
pIRES/VE2-ss-TEM1-TM using the calcium phos-
phate method. The cells were washed 24 h after
transfection and incubated with purified scFvs
(10 mg/ml) for 30 min, followed by incubation with
mouse anti-flag M2 antibody and TRITC-labeled goat
anti-mouse IgG. Finally, the cells were fixed in 3.7%
formaldehyde, embedded in gelvatol, pH 7.5 and were
examined with a Zeiss Axiophot epifluorescence
microscope.
2.10. Liposome preparation
Small unilamellar liposomes (SUV) in phosphate
buffer (PB, 67 mM, pH 7.4) with the composition of
HSPC:Cholesterol:DPPE:DiO at a molar ratio of
1:0.2:0.07:0.004 and a mean diameter of 100 nm
were prepared with a Lipexe extruder (Lipex
Biomembranes Inc., Vancouver, Canada) as described
by Marty et al. [17]. For cytotoxicity studies NOAC-
ETC (7.5 mol% referred to HSPC) was added to the
lipid mixture. Coupling of scFvs to liposomes was
performed as described previously [17].
2.11. Flow cytometry
IMR-32 and HT-29 cells were detached with
10 mM EDTA in PBSCC (PBS containing 0.41 mM
MgCl2 and 0.67 mM CaCl2) and washed once with
PBSCC. Aliquots of 106 cells were incubated with
scFvs (10 mg/ml) or fluorescence-labeled liposomes in
PBSCC for 30 min at 4 8C. Cells were washed twice
with PBSCC and scFvs were detected with mouse
C. Marty et al. / Cancer Letters 235 (2006) 298–308302anti-flag M2 antibody and FITC-labeled goat anti-
mouse IgG for 1 h at 4 8C. Cells were analyzed by
flow cytometry using a FACScan (Becton Dickinson,
Mountain View, CA) and quantified with the
CellQuest software (Becton Dickinson).
2.12. Cytotoxicity determination
Determination of cell viability was carried out as
described previously [23]. Briefly, IMR-32 and HT-29
cells (10 000 cells/well) were seeded in growth
medium for 24 h and cultured at 37 8C and 5% CO2
in 96 well plates. Where indicated liposome binding
was blocked by preincubation of the cells with a 100
fold excess of free scFv for 30 min. Liposomes
containing NOAC-ETC or free NOAC-ETC at
concentrations of 40 mM diluted in DMEM medium
1:1 (v/v) were added to the cells. After 1 h incubation,
the liposome containing medium was removed and
replaced by growth medium for 24 h. Cell viability
was determined with the WST-1 test using a Dynatech
MR 4000 plate reader. All measurements were carried
out in quadruplicates.Fig. 1. Analysis of recombinant proteins. Lanes 1–3: Coomassie-
stained SDS-PAGE showing GST (lane 1), GST-TEM1 (lane 2) and
scFv-CM6 (lane 3). Western blots show detection of GST (lane 4),
GST-TEM1 (lane 5) proteins by GST-specific antibody, and scFv-
CM6 by anti-flag M2 antibody.3. Results
3.1. Isolation, production and characterization
of GST-TEM1, scFv-CM6 and scFv-CM6-C
The extracellular part of TEM1 (amino acids
1–271) fused to the carboxyterminus of GST was
produced in E. coli with a yield of 2 mg/l, purified on
Glutathione-Sepharose and analyzed by SDS-PAGE
(Fig. 1, lane 2) and Western blotting (Fig. 1, lane 5).
The fusion protein had the expected molecular weight
of 64 kDa.
ScFvs specific for TEM1 were isolated from the
ETH-2 phage display library using GST-TEM1 fusion
protein immobilized on immunotubes. GST-specific
phages were removed first by panning with GST,
followed by three rounds of selection with GST-
TEM1. Eight distinct positive clones out of 90 tested
were identified. One clone, scFv-CM6, showed
excellent binding properties in ELISA and a high
production rate in bacteria and was used for scaled up
production. ScFv-CM6 was expressed in E. coli
HB2151 and exported to the bacterial periplasma viaa PelB leader peptide. The yield of purified protein
was typically 1–2 mg per 1 l of culture.
ScFv-CM6 was also produced in P. pastoris using
the expression vector pPICZaA. The sequence
was supplemented with a cysteine linker at the
carboxy-terminus as described previously [15]. This
scFv, termed scFv-CM6-C, was secreted into the
culture supernatant of transformed P. pastoris and its
expression was analyzed by SDS-PAGE and Western
blot. Production was 5–10 fold improved relative to
bacterial expression with yields up to 10 mg/l. ScFvs
produced in E. coli or P. pastoris were purified in one
step on a Protein A column. Fig. 1 shows detection
of scFv-CM6 by SDS-PAGE (lane 3) and Western
blotting (lane 6).3.2. Characterization of scFv-CM6 and scFv-CM6-C
Binding of scFv-CM6 and scFv-CM6-C to TEM1
was first demonstrated by ELISA. Purified recombi-
nant GST and GST-TEM1, respectively, immobilized
on 96 well plastic plates were incubated with
increasing concentrations of scFvs (Fig. 2(A)). The
affinity of scFv-CM6-C was identical to that of scFv-
CM6. Both scFvs did not bind to GST, BSA nor
untreated plastic. The binding properties of purified
scFv-CM6 and scFv-CM6-C were further character-
ized by Western blot analysis. GST and GST-TEM1
were transferred onto a PVDF membrane and
Fig. 2. Binding affinity of scFvs to purified GST-TEM1 (A) and
binding of scFv-CM6 to GST-TEM1 immobilized on a PVDF
membrane (B) and on Glutathione-Sepharose beads (C). (A) 96-
wells plates coated with GST-TEM1, GST, or BSA were incubated
with 0.01–1000 nM of purified scFvs for 1 h at RT. Binding was
detected with an anti-flag M2 antibody and a HRP-conjugated goat
anti-mouse IgG. Data are expressed as the meanG SD (nZ4). (B)
The proteins GST-TEM1 (lanes 1, 3) and GST (lanes 2, 4) were
detected with scFv-CM6 (lanes 1, 2) or the non-specific scFv-A1
(lanes 3, 4) used as primary antibodies in Western blot analysis. (C)
GST (lane 1), GST-TEM1 (lane 2) and untreated beads (lane 3)
were incubated with scFv-CM6 for 30 min, washed and analyzed on
Western blots using anti-flag M2 primary antibody.
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CM6 specifically bound to GST-TEM1 (lane 1) but
not to GST (lane 2), while the non-specific scFv-A1
bound neither to GST-TEM1 (lane 3) nor to GST(lane 4). Similar results were obtained for scFv-CM6-
C (data not shown). Moreover, specific binding of
scFv-CM6 and scFv-CM6-C was confirmed on GST-
TEM1 coupled to Glutathione-Sepharose. ScFv-CM6
recognized native GST-TEM1 protein as shown in
Fig. 2(C), lane 2, but not GST (lane 1) or empty beads
(lane 3). No binding was observed with scFv-A1 in all
assays. The cysteine-modified in P. pastoris produced
antibodies scFv-CM6-C and scFv-A1-C gave the
same results as their bacterial counterparts (data not
shown).
3.3. Binding of scFv-CM6 and scFv-CM6-C
to TEM1-expressing cells
To test whether our scFvs recognize TEM1 located
on the surface of cells, HEK 293T cells were
transiently transfected with a bicistronic vector
leading to expression of TEM1 fused to the signal
sequence and transmembrane part of VEGF receptor 2
and to co-expression of green fluorescent protein
(GFP). Transfection efficiency was determined by the
number of GFP positive cells (Fig. 3(A) and (C)).
TEM1 protein was detected on the cell membrane by
scFv-CM6 (Fig. 3(B)) while the control scFv-A1
showed no staining (Fig. 3(D)). Specific TEM1
recognition by scFv-CM6 was further confirmed by
flow cytometry. ScFv-CM6 recognized IMR-32 tumor
cells endogenously expressing TEM1 (Fig. 4(A)),
whereas no binding was detected on HT-29 cells that
lack TEM1 (Fig. 4(B)). Similar results were obtained
with scFv-CM6-C (data not shown).
3.4. Properties of scFv-CM6-C-immunoliposomes
ScFv-CM6-C was coupled to the surface of
liposomes as described earlier [17]. Fluorescence-
labeled scFv-CM6-C-immunoliposomes showed
higher binding activity to TEM1-expressing IMR-32
cells than control liposomes as examined by flow
cytometry (Fig. 4(C)) and no specific binding was
observed on TEM1-negative HT-29 cells (Fig. 4(D)).
3.5. Cytotoxicity of scFvCM6-C-NOAC-ETC-
immunoliposomes
Immunoliposomes and control liposomes contain-
ing NOAC-ETC were added to IMR-32 and HT-29
Fig. 3. Immunofluorescence staining of TEM1-expressing HEK 293T cells. Cells were transiently transfected with a bicistronic expression
vector encoding TEM1 and GFP. Cells were incubated with scFv-CM6 (B) or scFv-A1 (D) and stained with anti-flag M2 antibody followed by
TRITC-labeled goat anti-mouse IgG. GFP fluorescence identifying transfected cells is shown in panels A and C.
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determined after 24 h. As shown in Fig. 5, scFv-CM6-
C-NOAC-ETC-immunoliposomes reduced cell viabi-
lity of TEM1-expressing cells by 82% compared to
control NOAC-ETC-liposomes. Less toxicity was
observed when the TEM1-negative cell line HT-29
was treated with scFv-CM6-C-NOAC-ETC-immuno-
liposomes. To demonstrate the specificity of scFv-
CM6-immunoliposomes, IMR-32 cells were first
treated with soluble scFv-CM6-C followed by
incubation with cytotoxic immunoliposomes. The
toxicity of the immunoliposomes was almost com-
pletely blocked as shown in Fig. 5 (bar 4) while
preincubation with a non-specific control antibody
showed no blocking effects (Fig. 5, bar 5). This
experiment shows that TEM1-specific immunolipo-
somes preferentially kill TEM1-expressing cellswhile leaving control cells unaffected. Immunolipo-
somes without NOAC-ETC were not toxic (data not
shown) and serum had no influence on the effect of
liposomes loaded with NOAC-ETC (data not shown).
As expected, free NOAC-ETC showed similar
toxicity towards both cell lines (Fig. 5, bars 6 and 12).4. Discussion
Here we describe the isolation and characterization
of a single chain recombinant antibody, scFv-CM6
that recognizes tumor endothelial marker 1. TEM1 is
a membrane protein predominantly expressed on
tumor endothelial cells and on some tumor cells
and is therefore well suited for targeted tumor therapy
[3,4]. Other angiogenic markers such as endoglin,
Fig. 4. Binding of scFvs and immunoliposomes to TEM1-positive IMR-32 cells (A, C) and TEM1-negative HT-29 cells (B, D). Cells were
incubated with scFvs (A, B) or fluorescence-labeled DiO immunoliposomes (C, D) on ice for 30 min. ScFvs were stained with anti-flag M2
antibody and FITC-labeled goat anti-mouse IgG and analyzed by flow cytometry. Black bar in A, PZ0.0065, Black bar in C, PZ0.0037.
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fibronectin have been shown before to represent good
targets for tumor vasculature-specific cancer therapy
[24–27].
In the past years, phage display of peptides and
proteins has become an important method and was
successfully used in protein engineering, ligand–
receptor interaction studies and for generating
antibody fragments to target tissues in live organisms.
Phage display libraries such as the ETH-2 library
described by Pini et al. [9] are convenient tools to
isolate antibody fragments specific for a plethora of
antigens. Our scFv-CM6 was isolated by phage
display using the extracellular part of human TEM1
fused to GST and was initially produced in E. coli.
Since one of the factors limiting the application of
scFv therapy is the low amount that can be produced
by bacterial expression systems, we chose the yeast
P. pastoris to increase the production yield of scFv
proteins [15]. While recloning our scFv into the yeast
expression vector, we also added new features thatexpand their use as targeting reagents. Three cysteine
residues and a glycine linker were added at the
carboxyterminus of the scFv-CM6 sequence in order
to allow coupling the protein to drugs, toxins,
radioisotopes or for the linkage to the surface of
liposomes via a maleimide linker [17]. Bacterially and
yeast produced scFvs showed the same binding
properties on purified TEM1 protein (Fig. 2).
We next investigated whether scFv-CM6 is able to
recognize TEM1 expressed on the surface of living
cells. Whereas scFv-CM6 specifically bound to TEM1
located on the membrane of transiently transfected
HEK 293T cells and on tumor cells such as IMR-32
that endogenously express TEM1, control scFv
showed no binding (Figs. 3 and 4). This supports the
concept that TEM1-specific antibodies are excellent
tools for cell-specific targeting.
Immunoliposomes have been successfully used in
the past as carriers for therapeutic drugs, toxins,
radioisotopes or fluorescent markers for targeted
inhibition of tumor growth [28,29]. In our previous
Fig. 5. Cytotoxicity of scFv-immunoliposomes loaded with NOAC-
ETC tested on TEM1 positive IMR-32 and on TEM1 negative HT-
29 cells. Cells were incubated in 96 well plates for 1 h with scFv-
CM6-C-NOAC-ETC-immunoliposomes (bar 1), scFv-A1-C-
NOAC-ETC-immunoliposomes (bar 2) or control-NOAC-ETC-
liposomes (bar 3), preincubation was performed with free scFv-
CM6-C prior to scFv-CM6-C-NOAC-ETC-immunoliposomes (bar
4) or with free control scFv-A1-C prior to scFv-CM6-C-NOAC-
ETC-immunoliposomes (bar 5) or free NOAC-ETC (bar 6) with a
unique drug concentration of 40 mM. The bar numbers are equal for
both cell lines. Cell viability was measured after 24 h using WST-1
reagent. Data are expressed as the mean G SD (nZ4). ***PZ
0.0010.
C. Marty et al. / Cancer Letters 235 (2006) 298–308306study we demonstrated tumor-specific targeting of
immunoliposomes modified with a scFv recognizing
the ED-B isoform of fibronectin, an extracellular
matrix protein highly expressed in well vascularized
F9 tumors that can be grown in nude and Sv129 mice
[17]. In this study we coupled the cysteine-modified
TEM1 antibody (scFv-CM6-C) with an efficiency of
approximately 30% to liposomes taking advantage of
a coupling method that preserves protein activity. This
method is based on the conjugation of thiolated
proteins to carriers modified with cysteine-reactive
maleimide groups. Target cell-specific immunolipo-
somes offer the possibility to use nucleoside duplex
drugs in combination with water soluble cytotoxic
compounds such as e.g. doxorubicin or mitoxantrone.
Alternatively, anti-angiogenic molecules such as
fumagallin derivatives (TNP-470) can be concomi-
tantly incorporated into liposomes. Our scFv-CM6-C-
immunoliposomes were loaded with NOAC-ETC, a
cytotoxic amphiphilic nucleoside duplex molecule
recently developed by our laboratories. The chemicalcombination of NOAC [19] and ETC [20] gives
rise to a heterodinucleoside drug with high cytotox-
icity against solid tumors that can be efficiently
incorporated into the lipid membrane of liposomes.
Therapeutic targeting and cytotoxicity of our scFv-
CM6-C-NOAC-ETC-immunoliposomes were suc-
cessfully tested on TEM1-expressing cells as shown
in Fig. 5. Specificity of immunoliposome targeting
was further demonstrated by blocking TEM1 with
soluble free scFv which resulted in almost complete
inhibition of liposomal cytotoxicity.
Whether TEM1 is internalized or not is at present
unclear and the mechanism underlying drug uptake
into cells must be further investigated. The function of
TEM1 may be to concentrate liposomes on the surface
of target cells and thereby to promote their fusion with
the cell membrane. This will result in the release of
the drug into target cells.
Since the tumor vasculature is easily accessible
for drug carriers circulating in the blood, the use of
TEM1-targeted reagents represents a promising
strategy for cancer therapy. Such a therapy is
aimed predominantly at the destruction of the
genetically stable tumor vasculature which shows a
low mutation rate and is therefore expected to lead
to reduced therapy resistance. TEM1-specific target-
ing with immunoliposomes is a novel approach for
efficient anti-angiogenic therapy. As TEM1 is also
expressed on tumor cells, our scFv-CM6 represents
a useful reagent for tumor diagnosis. In addition, the
scFvs described here are promising tools to
investigate the role of TEM1 in the development
of new blood vessels, for instance in the vicinity of
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